Findings from a post hoc analysis of the phase 3 DIRECTION study highlight tezepelumab’s consistent benefit on asthma exacerbations across trigger categories.
Chris Ambrose, MD, MBA
Advertisement
Chris Ambrose, MD, MBA, is Franchise Head, US Biopharmaceuticals Medical, Respiratory, at AstraZeneca.
Articles by Chris Ambrose, MD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
2
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
3
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
4
What Are the Side Effects of Hair and Skin Supplements in Dermatology? With Rajani Katta, MD
5